Literature DB >> 24752615

Bufalin exerts inhibitory effects on IL-1β-mediated proliferation and induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes.

Yue-wen Chang1, Yong-fang Zhao, Yue-long Cao, Wei Gu, Jian Pang, Hong-sheng Zhan.   

Abstract

Rheumatoid arthritis fibroblast-like synoviocytes (RAFLSs) proliferate abnormally and resist apoptosis. Bufalin inhibits cell proliferation and induces apoptosis in human cancer cells. In this study, we explored the effects of bufalin on interleukin-1beta (IL-1β)-induced proliferation and apoptosis of RAFLSs. The cell proliferation and apoptosis were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide assay and annexin V/propidium iodide staining, respectively. Bufalin dose-dependently inhibited IL-1β-induced RAFLS proliferation. Mechanistically, bufalin decreased the activation of mitogen-activated protein kinases (MAPKs) and nuclear factor-kappa B (NF-κB), both of which are involved in IL-1β-mediated RAFLS proliferation. Moreover, bufalin induced apoptosis and mitochondrial damage of RAFLSs, which was associated with Bcl-2 downregulation, Bax upregulation, mitochondrial cytochrome c release, and enhanced cleavages of caspase-3 and poly-(ADP-ribose) polymerase. Collectively, our results reveal that bufalin suppresses IL-1β-induced proliferation of RAFLSs through MAPK and NF-κB signaling pathways and induces RAFLS apoptosis via the mitochondria-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24752615     DOI: 10.1007/s10753-014-9882-5

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  46 in total

1.  Bufalin induces G0/G1 phase arrest through inhibiting the levels of cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells.

Authors:  Wen-Wen Huang; Jai-Sing Yang; Shu-Jen Pai; Ping-Ping Wu; Shu-Jen Chang; Fu-Shin Chueh; Ming-Jen Fan; Shang-Ming Chiou; Hsiu-Maan Kuo; Chin-Chung Yeh; Po-Yuan Chen; Minoru Tsuzuki; Jing-Gung Chung
Journal:  Mutat Res       Date:  2012-01-20       Impact factor: 2.433

2.  In situ expression of protooncogenes and Fas/Fas ligand in rheumatoid arthritis synovium.

Authors:  H Asahara; T Hasunuma; T Kobata; H Inoue; U Muller-Ladner; S Gay; T Sumida; K Nishioka
Journal:  J Rheumatol       Date:  1997-03       Impact factor: 4.666

3.  Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.

Authors:  J Yang; X Liu; K Bhalla; C N Kim; A M Ibrado; J Cai; T I Peng; D P Jones; X Wang
Journal:  Science       Date:  1997-02-21       Impact factor: 47.728

4.  NF-kappaB-regulated expression of cellular FLIP protects rheumatoid arthritis synovial fibroblasts from tumor necrosis factor alpha-mediated apoptosis.

Authors:  Shaochun Bai; Hongtao Liu; Kun-Hung Chen; Polikseni Eksarko; Harris Perlman; Terry L Moore; Richard M Pope
Journal:  Arthritis Rheum       Date:  2004-12

Review 5.  Apoptosis in rheumatoid arthritis.

Authors:  Anja Baier; Ingmar Meineckel; Steffen Gay; Thomas Pap
Journal:  Curr Opin Rheumatol       Date:  2003-05       Impact factor: 5.006

6.  Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis.

Authors:  G Schett; M Tohidast-Akrad; J S Smolen; B J Schmid; C W Steiner; P Bitzan; P Zenz; K Redlich; Q Xu; G Steiner
Journal:  Arthritis Rheum       Date:  2000-11

Review 7.  Apoptosis as a therapeutic tool in rheumatoid arthritis.

Authors:  Richard M Pope
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

8.  Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent.

Authors:  B Foxwell; K Browne; J Bondeson; C Clarke; R de Martin; F Brennan; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

9.  FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis.

Authors:  Jörg Schedel; Renate E Gay; Peter Kuenzler; Christian Seemayer; Beat Simmen; Beat A Michel; Steffen Gay
Journal:  Arthritis Rheum       Date:  2002-06

10.  MLN51 and GM-CSF involvement in the proliferation of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis.

Authors:  Jinah Jang; Dae-Seog Lim; Young-Eun Choi; Yong Jeong; Seung-Ah Yoo; Wan-Uk Kim; Yong-Soo Bae
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  4 in total

1.  Indirubin inhibits the migration, invasion, and activation of fibroblast-like synoviocytes from rheumatoid arthritis patients.

Authors:  Mingcheng Huang; Lihui Wang; Shan Zeng; Qian Qiu; Yaoyao Zou; Maohua Shi; Hanshi Xu; Liuqin Liang
Journal:  Inflamm Res       Date:  2017-03-06       Impact factor: 4.575

2.  Bufalin Induces Apoptosis of Human Osteosarcoma U-2 OS Cells through Endoplasmic Reticulum Stress, Caspase- and Mitochondria-Dependent Signaling Pathways.

Authors:  Ching-Hsiao Lee; Yung-Luen Shih; Mei-Hui Lee; Man-Kuan Au; Yung-Liang Chen; Hsu-Feng Lu; Jing-Gung Chung
Journal:  Molecules       Date:  2017-03-10       Impact factor: 4.411

Review 3.  New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin.

Authors:  Chien-Shan Cheng; Jiaqiang Wang; Jie Chen; Kuei Ting Kuo; Jian Tang; Huifeng Gao; Lianyu Chen; Zhen Chen; Zhiqiang Meng
Journal:  Cancer Cell Int       Date:  2019-04-11       Impact factor: 5.722

Review 4.  Apoptosis Induction of Fibroblast-Like Synoviocytes Is an Important Molecular-Mechanism for Herbal Medicine along with its Active Components in Treating Rheumatoid Arthritis.

Authors:  Qing Zhang; Jia Liu; Mengmeng Zhang; Shujun Wei; Ruolan Li; Yongxiang Gao; Wei Peng; Chunjie Wu
Journal:  Biomolecules       Date:  2019-11-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.